Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Pharm Res
1999 Jun 01;166:904-8. doi: 10.1023/a:1018838405987.
Show Gene links
Show Anatomy links
Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.
Tokui T
,
Nakai D
,
Nakagomi R
,
Yawo H
,
Abe T
,
Sugiyama Y
.
???displayArticle.abstract???
PURPOSE: We previously demonstrated the HMG-CoA reductase inhibitor, pravastatin, is actively taken up into isolated rat hepatocytes through multispecific organic anion transporters. The present study examined whether a newly cloned organic anion transporting polypeptide (oatp2) transports pravastatin.
METHODS: We investigated functional expression of oatp2 in Xenopus laevis oocytes, to examine [14C] pravastatin uptake.
RESULTS: [14C] Pravastatin (30 microM) uptake into oatp2 cRNA-injected oocytes was 40 times higher than that of water-injected control oocytes. The oatp2-mediated pravastatin uptake was Na+-independent and saturable. The Michaelis-Menten constant was 37.5+/-9.9 microM, a level comparable to that obtained in isolated rat hepatocytes in our previous study. As is the case with rat hepatocytes, the uptake of pravastatin (30 microM) was inhibited by 300 microM concentrations of taurocholate, cholate, bromosulfophthalein, estradiol-17beta-glucuronide, and simvastatin acid, but not by para-aminohippurate. On the other hand, [14C] simvastatin acid (30 microM) uptake of oatp2 cRNA-injected oocytes was not significantly different from that of water-injected oocytes.
CONCLUSIONS: The cloned oatp2 was identified as the transporter responsible for the active hepatocellular pravastatin uptake.
Abe,
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.
1998, Pubmed
Abe,
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.
1998,
Pubmed
Bergwerk,
Immunologic distribution of an organic anion transport protein in rat liver and kidney.
1996,
Pubmed
,
Xenbase
Bossuyt,
Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver.
1996,
Pubmed
,
Xenbase
Eckhardt,
The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide.
1996,
Pubmed
,
Xenbase
Goldin,
Maintenance of Xenopus laevis and oocyte injection.
1992,
Pubmed
,
Xenbase
Grundy,
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
1988,
Pubmed
Ishigami,
Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.
1995,
Pubmed
Jacquemin,
Expression cloning of a rat liver Na(+)-independent organic anion transporter.
1994,
Pubmed
,
Xenbase
Kakyo,
Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2).
1999,
Pubmed
,
Xenbase
Komai,
Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.
1992,
Pubmed
Komai,
Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture.
1992,
Pubmed
Kouzuki,
Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes.
1999,
Pubmed
Kullak-Ublick,
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
1994,
Pubmed
,
Xenbase
Li,
Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter.
1998,
Pubmed
,
Xenbase
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Noé,
Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain.
1997,
Pubmed
,
Xenbase
Saheki,
In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
1994,
Pubmed
Sekine,
Expression cloning and characterization of a novel multispecific organic anion transporter.
1997,
Pubmed
,
Xenbase
Tamai,
Proton-cotransport of pravastatin across intestinal brush-border membrane.
1995,
Pubmed
Tsujita,
CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.
1986,
Pubmed
Yamazaki,
Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.
1996,
Pubmed
Yamazaki,
Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.
1993,
Pubmed
Yamazaki,
Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system.
1996,
Pubmed
Yamazaki,
Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
1997,
Pubmed
Ziegler,
Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.
1992,
Pubmed
van Vliet,
Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types.
1995,
Pubmed
